Cargando…

Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production

Current influenza vaccines have relatively low effectiveness, especially against antigenically drifted strains, the effectiveness is even lower in the elderly and immunosuppressed individuals. We have previously shown in a randomized clinical trial that the topical application of a toll-like recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Can, To, Kelvin K. W., Zhang, Anna J. X., Lee, Andrew C. Y., Zhu, Houshun, Mak, Winger W. N., Hung, Ivan F. N., Yuen, Kwok-Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194170/
https://www.ncbi.nlm.nih.gov/pubmed/30369932
http://dx.doi.org/10.3389/fimmu.2018.02370
_version_ 1783364183822172160
author Li, Can
To, Kelvin K. W.
Zhang, Anna J. X.
Lee, Andrew C. Y.
Zhu, Houshun
Mak, Winger W. N.
Hung, Ivan F. N.
Yuen, Kwok-Yung
author_facet Li, Can
To, Kelvin K. W.
Zhang, Anna J. X.
Lee, Andrew C. Y.
Zhu, Houshun
Mak, Winger W. N.
Hung, Ivan F. N.
Yuen, Kwok-Yung
author_sort Li, Can
collection PubMed
description Current influenza vaccines have relatively low effectiveness, especially against antigenically drifted strains, the effectiveness is even lower in the elderly and immunosuppressed individuals. We have previously shown in a randomized clinical trial that the topical application of a toll-like receptor 7 agonist, imiquimod, just before intradermal influenza vaccine could expedite and augment antibody response, including to antigenically-drifted strains. However, the mechanism of this vaccine and imiquimod combination approach is poorly understood. Here, we demonstrated that imiquimod alone directly activated purified mouse peritoneal B cells. When combined with inactivated H1N1/415742Md influenza virus particle (VP) as vaccine, co-stimulation of mouse peritoneal B cells in vitro induced stronger activation, proliferation, and production of virus-antigen specific IgM and IgG. Intraperitoneal injection of a combination of VP and imiquimod (VCI) was associated with an increased number of activated B cells with enhanced expression of CD86 in the mesenteric draining lymph nodes (mesLN) and the spleen at 18 h after injection. Three days after immunization with VCI, mouse spleen showed significantly more IgM and IgG secreting cells upon in vitro re-stimulation with inactivated virus, mouse sera were detected with viral neutralizing antibody. Transfer of these spleen B cells to naïve mice improved survival after lethal dose of H1N1/415742Md challenge. More importantly, the functional response of VCI-induced B cell activation was demonstrated by early challenge with a lethal dose of H1N1/415742Md influenza virus at 3 days after immunization. The spleen and mediastinal lymph nodes (mdLN) in mice immunized with VCI had germinal center formation, and significantly higher number of plasmablasts, plasma cells, and virus-antigen specific IgM and IgG secreting cells at only 3–4 days post virus challenge, compared with those of mice that have received imiquimod, inactivated virus alone or PBS. Serum virus-specific IgG2a, IgG2b, and IgG1 and bronchoalveolar lavage fluid (BALF) virus-specific IgA at 3 or 4 days post challenge were significantly higher in mice immunized with VCI, which had significantly reduced lung viral load and 100% survival. These findings suggested that imiquimod accelerates the vaccine-induced antibody production via inducing rapid differentiation of naïve B cells into antigen-specific antibody producing cells.
format Online
Article
Text
id pubmed-6194170
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61941702018-10-26 Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production Li, Can To, Kelvin K. W. Zhang, Anna J. X. Lee, Andrew C. Y. Zhu, Houshun Mak, Winger W. N. Hung, Ivan F. N. Yuen, Kwok-Yung Front Immunol Immunology Current influenza vaccines have relatively low effectiveness, especially against antigenically drifted strains, the effectiveness is even lower in the elderly and immunosuppressed individuals. We have previously shown in a randomized clinical trial that the topical application of a toll-like receptor 7 agonist, imiquimod, just before intradermal influenza vaccine could expedite and augment antibody response, including to antigenically-drifted strains. However, the mechanism of this vaccine and imiquimod combination approach is poorly understood. Here, we demonstrated that imiquimod alone directly activated purified mouse peritoneal B cells. When combined with inactivated H1N1/415742Md influenza virus particle (VP) as vaccine, co-stimulation of mouse peritoneal B cells in vitro induced stronger activation, proliferation, and production of virus-antigen specific IgM and IgG. Intraperitoneal injection of a combination of VP and imiquimod (VCI) was associated with an increased number of activated B cells with enhanced expression of CD86 in the mesenteric draining lymph nodes (mesLN) and the spleen at 18 h after injection. Three days after immunization with VCI, mouse spleen showed significantly more IgM and IgG secreting cells upon in vitro re-stimulation with inactivated virus, mouse sera were detected with viral neutralizing antibody. Transfer of these spleen B cells to naïve mice improved survival after lethal dose of H1N1/415742Md challenge. More importantly, the functional response of VCI-induced B cell activation was demonstrated by early challenge with a lethal dose of H1N1/415742Md influenza virus at 3 days after immunization. The spleen and mediastinal lymph nodes (mdLN) in mice immunized with VCI had germinal center formation, and significantly higher number of plasmablasts, plasma cells, and virus-antigen specific IgM and IgG secreting cells at only 3–4 days post virus challenge, compared with those of mice that have received imiquimod, inactivated virus alone or PBS. Serum virus-specific IgG2a, IgG2b, and IgG1 and bronchoalveolar lavage fluid (BALF) virus-specific IgA at 3 or 4 days post challenge were significantly higher in mice immunized with VCI, which had significantly reduced lung viral load and 100% survival. These findings suggested that imiquimod accelerates the vaccine-induced antibody production via inducing rapid differentiation of naïve B cells into antigen-specific antibody producing cells. Frontiers Media S.A. 2018-10-12 /pmc/articles/PMC6194170/ /pubmed/30369932 http://dx.doi.org/10.3389/fimmu.2018.02370 Text en Copyright © 2018 Li, To, Zhang, Lee, Zhu, Mak, Hung and Yuen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Can
To, Kelvin K. W.
Zhang, Anna J. X.
Lee, Andrew C. Y.
Zhu, Houshun
Mak, Winger W. N.
Hung, Ivan F. N.
Yuen, Kwok-Yung
Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
title Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
title_full Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
title_fullStr Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
title_full_unstemmed Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
title_short Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
title_sort co-stimulation with tlr7 agonist imiquimod and inactivated influenza virus particles promotes mouse b cell activation, differentiation, and accelerated antigen specific antibody production
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194170/
https://www.ncbi.nlm.nih.gov/pubmed/30369932
http://dx.doi.org/10.3389/fimmu.2018.02370
work_keys_str_mv AT lican costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT tokelvinkw costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT zhangannajx costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT leeandrewcy costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT zhuhoushun costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT makwingerwn costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT hungivanfn costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction
AT yuenkwokyung costimulationwithtlr7agonistimiquimodandinactivatedinfluenzavirusparticlespromotesmousebcellactivationdifferentiationandacceleratedantigenspecificantibodyproduction